Cross - validation | Src inhibitors | Src non-inhibitors | Q | C | ||||||
---|---|---|---|---|---|---|---|---|---|---|
No of training/ testing inhibitors | TP | FN | SE | No of training/testing non-inhibitors | TN | FP | SP | |||
1 | 1362/341 | 302 | 39 | 88.56% | 50654/12664 | 12635 | 29 | 99.77% | 99.48% | 0.896 |
2 | 1362/341 | 313 | 28 | 91.79% | 50654/12664 | 12620 | 44 | 99.65% | 99.45% | 0.894 |
3 | 1362/341 | 311 | 30 | 91.20% | 50654/12664 | 12610 | 54 | 99.57% | 99.35% | 0.878 |
4 | 1363/340 | 316 | 24 | 92.94% | 50655/12663 | 12619 | 44 | 99.65% | 99.48% | 0.901 |
5 | 1363/340 | 302 | 38 | 88.82% | 50655/12663 | 12632 | 31 | 99.76% | 99.47% | 0.895 |
Average | Â | Â | Â | 90.66% | Â | Â | Â | 99.68% | 99.44% | 0.893 |
SD | Â | Â | Â | 0.0191 | Â | Â | Â | 0.0008 | 0.0005 | 0.0085 |
SE | Â | Â | Â | 0.0085 | Â | Â | Â | 0.0004 | 0.0002 | 0.0038 |